Table 4. BRG1-negative tumors have splicing defects.
| Tumor | BP | AA | AA | Amino Acids | Exons | Domains | In/out | Inactivate | Epitope | Wild type |
|---|---|---|---|---|---|---|---|---|---|---|
| Deleted | Start | End | Deleted | Effected | Deleted | Frame | Protein | Present; IHC | Band | |
| 1832 | 237 | 78 | 157 | 79 | 4-5 | -- | In | No? | No | No |
| 2459 | 616 | 29 | 234 | 205 | 3-5 | QLQ | Out | yes | No | No |
| 2011 | 909 | 853 | 1156 | 303 | 19-26 | Dead box; helicase | In | yes | Yes | No |
| 2217 | 861 | 851 | 1138 | 287 | 19-26 | Dead box; helicase | In | yes | Yes | Yes |
| 2306 | 861 | 851 | 1138 | 287 | 19-26 | Dead box; helicase | In | yes | Yes | Yes |
| 2359 | 273 | 654 | 745 | 91 | 16-17 | -- | In | No? | Yes | yes |
| 2514 | 127 | 360 | 402 | 42 | 8 | -- | Out | yes | Yes | No |
| 2425 | 127 | 360 | 402 | 42 | 2 | -- | Out | yes | Yes | No |
| 2453 | 783 | 1134 | 1395 | 261 | 27-32 | SnAC | Out | yes | Yes | Yes |
| 2705 | 96 | 1391 | 1423 | 32 | 31 | -- | Out | yes | Yes | Yes |
| 2706 | 753 | 1219 | 1470 | 251 | 27-32 | SnAC | In | yes | Yes | No |
| 2600 | 100 | 774 | 807 | 33 | 28-29 | -- | Out | yes | Yes | Yes |
| 2645 | 712 | 876 | 1113 | 237 | 20-25 | Dead box | Out | yes | Yes | No |
| 2700 | 831 | 530 | 807 | 277 | 11-17 | DEADc; BRK | In | yes | Yes | Yes |
| 2472 | 818 | 543 | 816 | 273 | 11-17 | DEADc; BRK | Out | yes | Yes | No |
| 2733 | 123 | 667 | 708 | 41 | 15 | -- | In | No? | Yes | Yes |
Each primary tumor found to harbor splice variants is presented. The number of base pairs (bp) deleted is shown in the second column. In the third and fourth columns, the amino acid (AA) start and end values are given, respectively, followed by the number of amino acids that are deleted in the fifth column. The exons that are spliced out partially or completely in a given tumor are indicated in the sixth column whereas the domains of the BRG1 protein that are affected by the splicing defects are listed in the seventh column. Whether or not the splicing defects resulted in the frame-shift of the protein and the inactivation of the protein are indicated in the eighth column. The ninth column lists whether or not BRG1 would be expected to be inactivated due to this aberrant splicing event. In addition, the tenth column lists whether or not the BRG1 antibody epitope might be expected to be omitted by the aberrant BRG1 splicing. Presence of a wild type band observed after nested PCR of the cDNA is shown in the eleventh (last) column. The shading indicates the tumors in which loss of BRG1 expression would be expected to occur.